Related Experiment Video
Updated: Jul 15, 2025
Tissue Engineering of a Human 3D in vitro Tumor Test System
Published on: August 6, 2013
Identifying the effectiveness of 3D culture systems to recapitulate breast tumor tissue in situ
Katarzyna A Ludwik1, Frances R Greathouse1, Samuel Han2
1Department Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Purpose:
Breast cancer heterogeneity contributes to chemotherapy resistance and decreased patient survival. To improve patient outcomes it is essential to develop a technology that is able to rapidly select the most efficacious therapy that targets the diverse phenotypes present within the tumor. Breast cancer organoid technologies are proposed as an attractive approach for evaluating drug responses prior to patient therapy. However, there remain challenges in evaluating the effectiveness of organoid cultures to recapitulate the heterogeneity present in the patient tumor in situ.
Method:
Organoids were generated from seven normal breast and nineteen breast cancer tissues diagnosed as estrogen receptor positive or triple negative. The Jensen-Shannon divergence index, a measure of the similarity between distributions, was used to compare and evaluate heterogeneity in starting tissue and their resultant organoids. Heterogeneity was analyzed using cytokeratin 8 and cytokeratin 14, which provided an easily scored readout.
Results:
In the in vitro culture system HER1 and FGFR were able to drive intra-tumor heterogeneity to generate divergent phenotypes that have different sensitivities to chemotherapies.
Conclusion:
Our methodology, which focuses on quantifiable cellular phenotypes, provides a tractable system that complements omics approaches to provide an unprecedented view of heterogeneity and will enhance the identification of novel therapies and facilitate personalized medicine.
Insights
Breast cancer organoids can model tumor heterogeneity to predict chemotherapy response. This technology aids in selecting effective treatments for diverse cancer phenotypes, improving patient survival.
Area of Science:
- Oncology
- Biotechnology
- Genomics
Background:
- Breast cancer heterogeneity is a major cause of chemotherapy resistance and poor patient outcomes.
- Developing technologies to rapidly assess drug efficacy against diverse tumor phenotypes is crucial for personalized medicine.
Purpose of the Study:
- To evaluate breast cancer organoid cultures for their ability to recapitulate patient tumor heterogeneity.
- To establish a method for assessing drug responses in organoids that reflects in vivo tumor characteristics.
Main Methods:
- Organoids were generated from normal and malignant breast tissues (ER-positive and triple-negative).
- Jensen-Shannon divergence was used to quantify heterogeneity in tissues and organoids.
- Cytokeratin 8 and 14 expression analyzed heterogeneity.
Main Results:
- HER1 and FGFR signaling in vitro drove intra-tumor heterogeneity, creating divergent phenotypes.
- These divergent phenotypes exhibited varying sensitivities to chemotherapies.
Conclusions:
- A methodology using quantifiable cellular phenotypes in organoids offers a tractable system.
- This approach complements omics methods, providing insights into heterogeneity for novel therapy identification and personalized medicine.
